ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

11213	Companies
248508	Keywords
176266	Articles
134390	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 10/19/2026 at 07:35, 2 days 22 hours ago

OSE Immunotherapeutics Reveals Promising Phase 2 Results with Tedopi® for Lung Cancer

OSE Immunotherapeutics Non-Small Cell Lung Cancer Phase 2 Results Tedopi® Combi-TED Trial
PRESS RELEASE

published on 10/19/2026 at 07:30, 2 days 22 hours ago

OSE Immunotherapeutics Reports Positive Topline Results of Combi-TED Phase 2 Randomized Trial with Tedopi® (OSE2101) in metastatic Non-Small Cell Lung Cancer
OSE Immunotherapeutics reports positive results from Combi-TED Phase 2 trial with Tedopi® in metastatic NSCLC. Study to be presented at ESMO 2026. KOL webcast scheduled

Phase 2 Trial OSE Immunotherapeutics Tedopi Combi-TED Metastatic NSCLC
BRIEF

published on 10/15/2026 at 07:35, 6 days 22 hours ago

OSE Immunotherapeutics to Present at Chardan Healthcare Conference

Immuno-oncology Investor Meetings Healthcare Conference OSE Immunotherapeutics Biotech Presentation
PRESS RELEASE

published on 10/15/2026 at 07:30, 6 days 22 hours ago

OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
OSE Immunotherapeutics to present at Chardan’s 10th Annual Healthcare Conference in New York, USA. CEO to participate in a fireside chat on October 20, 2026

Immuno-oncology OSE Immunotherapeutics Chardan's 10th Annual Healthcare Conference Immuno-inflammation Clinical-stage Biotech
BRIEF

published on 09/23/2026 at 07:35, 28 days 22 hours ago

Results of Combi-TED presented by OSE Immunotherapeutics

Lung Cancer OSE Immunotherapeutics Tedopi® Phase 2 Combi-TED ESMO Congress 2026
BRIEF

published on 09/23/2026 at 07:35, 28 days 22 hours ago

Topline Results of Tedopi® in Lung Cancer to be Presented at ESMO 2026

Clinical Study NSCLC Phase 2 Trial Tedopi® ESMO 2026
PRESS RELEASE

published on 09/23/2026 at 07:30, 28 days 22 hours ago

OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
OSE Immunotherapeutics presents Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at ESMO 2026 Meeting. The trial evaluates Tedopi® in second-line treatment for metastatic NSCLC

OSE Immunotherapeutics Non-Small Cell Lung Cancer Tedopi® ESMO 2026 Combi-TED
BRIEF

published on 08/28/2026 at 07:35, 1 month 24 days ago

OSE Immunotherapeutics to Host Webcast on Lusvertikimab for Inflammatory Bowel Diseases

Clinical Trials Inflammatory Bowel Diseases OSE Immunotherapeutics Lusvertikimab Webcast Event
BRIEF

published on 08/28/2026 at 07:35, 1 month 24 days ago

OSE Immunotherapeutics: Webcast on Lusvertikimab with Experts

Webcast Inflammatory Diseases OSE Immunotherapeutics Medical Experts Lusvertikimab
PRESS RELEASE

published on 08/28/2026 at 07:30, 1 month 24 days ago

OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
OSE Immunotherapeutics to host KOL webcast on lusvertikimab, discussing IL-7R biology, CoTiKis trial results, and future plans on September 2, 2026

Inflammatory Bowel Diseases OSE Immunotherapeutics Lusvertikimab KOL Webcast IL-7R Biology

1 2 ... 8

Accesswire

Published on 10/21/2026 at 22:00, 7 hours 42 minutes ago

Prospect Ridge Announces Second Tranche Closing of Critical Metals Flow-Through Unit Private Placement
Published on 10/21/2026 at 15:00, 14 hours 42 minutes ago

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Published on 10/21/2026 at 14:40, 15 hours 2 minutes ago

Axo Metals Receives Approval to Trade on the OTCQB Venture Market Under the Symbol AXOCF
Published on 10/21/2026 at 14:30, 15 hours 12 minutes ago

Fermi Provides Letter to Shareholders from CEO Lee McIntire on Financing Fermi's Next Chapter
Published on 10/21/2026 at 14:00, 15 hours 42 minutes ago

Nine Mile Metals DDH WD-26-18 Intersects A High Grade VMS Lens, Returning 7.13% Cu-Eq Over 11.65 M Including 9.93% Cu-Eq Over 6.70 M And 10.46% Cu-Eq Over 4.80 M, With An Additional Upper 31.50m Copper Stringer Zone

View all ACCESSWIRE

EQS Group

Published on 10/22/2026 at 05:25, 16 minutes ago

IMOU launches IMOU SENSE™: Elevating Smart Security from Detection to True Scene Understanding
Published on 10/22/2026 at 05:20, 21 minutes ago

All-New TIGGO7 and TIGGOX7 Make Global Debuts at CHERY Brand Night, Celebrating "Together. For Family"
Published on 10/22/2026 at 04:05, 1 hour 36 minutes ago

Blokees Exhibits 900+ Products at 2026 China Toy Expo, Continuing to Advance Product Competitiveness
Published on 10/22/2026 at 00:00, 5 hours 41 minutes ago

EQS-Adhoc: Marley Spoon Group SE: Extension and increase of restructuring bridge financing for Marley Spoon SE
Published on 10/21/2026 at 23:38, 6 hours 4 minutes ago

QIAGEN und EQT Private Equity geben Einigung über ein empfohlenes freiwilliges öffentliches Übernahmeangebot in bar bekannt

Les Echos

Published on 10/21/2026 at 18:00, 11 hours 42 minutes ago

Saint-Gobain accelerates its growth in Egypt with the opening of two new production capacities
Published on 10/21/2026 at 17:59, 11 hours 43 minutes ago

Covivio Hotels : Revenues up +4.7% at end-September 2026
Published on 10/21/2026 at 17:45, 11 hours 57 minutes ago

Covivio - Q3 2026 activity : Accelerating organic revenue growth supported by strong operational execution
Published on 10/21/2026 at 17:40, 12 hours 2 minutes ago

Eiffage has signed a memorandum of understanding with the LOSC regarding the proposed disposal of the companies in charge of the management of the Decathlon Arena - Stade Pierre-Mauroy and its ancillary areas
Published on 10/21/2026 at 17:39, 12 hours 3 minutes ago

Solocal - Q3 2026 Revenue and Activity

View all LES ECHOS COMFI WIRE